Acetylcholinesterase inhibitors (ChEI) are the global standard of care for the symptomatic
treatment of Alzheimer's disease (AD) and show significant positive effects in …

Neuroinflammation and cholinergic dysfunction, leading to cognitive impairment, are
hallmarks of aging and neurodegenerative disorders, including Alzheimer's disease (AD) …

Background The mainstay of therapy for many neurodegenerative dementias still relies on
acetylcholinesterase inhibitors (AChEI); however, there is debate on various aspects of such …

Alpinia oxyphylla Miq.(ie, A. oxyphylla), a traditional Chinese medicine, can exert
neuroprotective effects in ameliorating mild cognitive impairment and improving the …

Introduction Cholinergic dysfunction, demonstrated in the late 1970s and early 1980s, led to
the introduction of acetylcholinesterase inhibitors (AChEIs) in 1993 (Tacrine) to enhance …

Symptomatic interventions for patients with dementia involve anti-dementia drugs to improve
cognition, psychotropic drugs for the treatment of behavioral disorders (BDs), and different …

The α7 nicotinic receptor (α7 nAChR) is an important entry point for Ca 2+ into the cell,
which has broad and important effects on gene expression and function. The gene …

Dementia is a syndrome of global and progressive deterioration of cognitive skills,
especially memory, learning, abstract thinking, and orientation, usually affecting the elderly …

The α7 nicotinic acetylcholine receptor (CHRNA7) modulates the inflammatory response by
activating the cholinergic anti-inflammatory pathway. CHRFAM7A, the human-restricted …

The development of Alzheimer's disease therapeutics has been challenging, with 99% of
clinical trials failing to find a significant difference between drug and placebo. While the …